Cancer is the second leading cause of death globally, responsible for 9.7 million deaths in 2022. The advent of novel therapeutic approaches for cancer, in conjunction with significant advancements in intensive care management for critically ill Oncology patientsoncology patients, has resulted in improved prognostic outcomes and increased survival rates. Recent evaluations of traditional comorbidity criteriaComorbidity criteria for admission to intensive care units (ICUs) have revealed limitations when these criteria are applied to this patient population. The risk factors associated with mortality, particularly the presence of multiple organ failures, provide crucial insights into the determinants of prognosis within the ICU setting. The incidence of cancer patients requiring admission to ICUs has increased, which is largely due to complications associated with the disease as well as side effects stemming from treatment therapies. Approximately 5% of individuals diagnosed with cancer are estimated to require admission to the ICU within a 2-year period following their diagnosis. Survival ratesSurvival rates for cancer patients who are admitted to the ICU have significantly increased; therefore, the denial of admission based solely on a cancer diagnosis is unjustifiable. Specialists who care for critically ill patients with cancer should adopt proactive measures to mitigate the risk of in-hospital mortality. This involves the early identification of patients experiencing initial stages of organ failure. ICU admission is crucial, as it facilitates the prevention, detection, and treatment of organ dysfunction, thereby providing comprehensive support for cancer patients who qualify for such care to impact their outcome. Currently, the management of these patients poses considerable challenges for oncologists, hematologists, surgical oncologists, and specialists in critical care medicine.